Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.88 USD
Change Today 0.00 / 0.00%
Volume 6.3K
ARWR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
Frankfurt
As of 9:32 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

arrowhead research corp (ARWR) Snapshot

Open
$6.88
Previous Close
$6.84
Day High
$7.07
Day Low
$6.83
52 Week High
09/9/14 - $17.42
52 Week Low
12/4/14 - $4.95
Market Cap
407.6M
Average Volume 10 Days
1.1M
EPS TTM
$-1.43
Shares Outstanding
59.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARROWHEAD RESEARCH CORP (ARWR)

Related News

No related news articles were found.

arrowhead research corp (ARWR) Related Businessweek News

No Related Businessweek News Found

arrowhead research corp (ARWR) Details

Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. The company was formerly known as InterActive Group, Inc. Arrowhead Research Corporation was incorporated in 1989 and is headquartered in Pasadena, California.

81 Employees
Last Reported Date: 11/25/14
Founded in 1989

arrowhead research corp (ARWR) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $543.6K
Chief Financial Officer
Total Annual Compensation: $293.4K
Chief Operating Officer
Total Annual Compensation: $384.2K
Vice President of Strategy & Program Manageme...
Total Annual Compensation: $222.8K
Chief Scientific Officer
Total Annual Compensation: $226.4K
Compensation as of Fiscal Year 2014.

arrowhead research corp (ARWR) Key Developments

Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency

Arrowhead Research Corporation announced that it dosed the first patient in Part B of a Phase 1 clinical trial of ARC-AAT. ARC-AAT is Arrowhead’s RNAi-based drug candidate for the treatment of liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD) that was recently granted orphan drug designation by the United States Food and Drug Administration. The clinical trial is currently enrolling patients at a single center in Australia and the company intends to open additional sites for enrollment in Europe, pending regulatory permission to proceed. The company expects to complete enrollment of the Phase 1 study by the end of 2015. The ongoing Phase 1 trial of ARC-AAT is a multi-center, randomized, placebo-controlled, double-blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels. The study has been enrolling in dose cohorts of six participants each, with participants randomized at a ratio of 2:1 (active: placebo) to receive a single intravenous injection of either ARC-AAT or placebo (normal saline). The study consists of two parts; Part A in healthy volunteers, which has been completed, and Part B to be conducted in patients with PiZZ genotype AATD. Dosing in patients begins at the high dose level used in healthy volunteers and then continued dose escalation may proceed under the protocol. The study evaluates participants for 28 days following dosing, with additional follow-up if needed every 2 weeks until AAT levels return to baseline.

Arrowhead Research Corp. Receives Regulatory Clearance to Begin Additional Phase 2B Studies of Hepatitis B Candidate Arc-520

Arrowhead Research Corporation announced that its Clinical Trial Application for ARC-520, it's clinical candidate for chronic hepatitis B infection (HBV), has been approved by Germany’s Federal Institute for Drugs and Medical Devices. The company now has regulatory clearance in Germany for two additional Phase 2b multiple-dose studies of ARC-520 to be conducted in parallel. Arrowhead awaits final IRB approval from the sites, which are expected shortly, and in addition, the company is engaged with regulatory authorities from Hong Kong and South Korea to open additional sites for these studies. Arrowhead will provide guidance in the future on timing for release of data from these studies. The studies titled Heparc-2002 and Heparc-2003 will enroll patients with chronic HBV infection that are e-antigen (HBeAg) negative and HBeAg positive, respectively. Each study is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study intended to evaluate two dose levels in parallel of ARC-520 in combination with entecavir or tenofovir in patients with immune active chronic HBV infection. The 2002 and 2003 studies are planned to enroll up to 60 and 90 patients, respectively. In each study, patients will be randomized to receive four doses, once every 4 weeks, of either 1 mg/kg ARC-520, 2 mg/kg ARC-520, or placebo at a ratio of 1:1:1. For each patient, the duration of the study is approximately 33 weeks, from screening to the Day 169 follow-up visit. For each study, a planning interim analysis will be performed when 54 patients have completed their Day 71 visit. This analysis will be used to plan future studies only and will not impact the enrollment or conduct of Heparc-2002 and -2003. Based on the interim results, the company will decide whether higher multiple-doses would be likely to lead to increased activity, in which case higher doses may be evaluated in one or more additional studies. The primary objective of the 2002 and 2003 studies is to evaluate the depth of hepatitis B surface antigen (HBsAg) decline in response to multiple doses of ARC-520 compared to placebo as a measure of drug activity. Secondary objectives include the assessment of safety and tolerability and multi-dose pharmacokinetics of ARC-520 when co-administered with entecavir or tenofovir, in addition to other exploratory objectives.

Arrowhead Research Corp. Receives Orphan Drug Designation for ARC-AAT

Arrowhead Research Corporation announced the United States Food and Drug Administration has granted ARC-AAT orphan drug designation. ARC-AAT is Arrowhead’s RNAi-based therapeutic candidate being investigated for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency, a rare genetic disease that severely damages the liver and lungs of affected children and adults. Arrowhead is currently conducting part B of a Phase 1 study of ARC-AAT in patients with PiZZ genotype AATD. The ongoing Phase 1 trial of ARC-AAT is a multi-center, randomized, placebo-controlled, double-blind, single dose-escalation first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels. The study has been enrolling in dose cohorts of six participants each, with participants randomized at a ratio of 2:1 (active: placebo) to receive a single intravenous injection of either ARC-AAT or placebo (normal saline). The study consists of two parts; Part A in healthy volunteers, which has been completed, and Part B to be conducted in patients with PiZZ genotype AATD. The study evaluates participants for 28 days following dosing, with additional follow-up if needed every 2 weeks until AAT levels return to baseline. The FDA Office of Orphan Products Development mission is to advance the evaluation and development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. In fulfilling that task, OOPD evaluates scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. Orphan drug designation provides incentives for sponsors to develop products for rare diseases. These incentives include increased engagement with FDA on drug development activities, exemption from all future product-specific regulatory fees, the opportunity to apply for R&D funding, tax credits, an increased chance of priority review, and 7 years of orphan exclusivity at time of New Drug Application approval.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARWR:US $6.88 USD 0.00

ARWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARWR.
View Industry Companies
 

Industry Analysis

ARWR

Industry Average

Valuation ARWR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,262.0x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 962.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARROWHEAD RESEARCH CORP, please visit www.arrowheadresearch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.